Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
Launched by ASTRAZENECA · May 3, 2006
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pre-menopausal women aged 18 years or over with histologically/cytologically-confirmed oestrogen receptor positive (ER +ve) breast cancer
- • World Health Organization (WHO) performance status of 0, 1, or 2
- • Provided written informed consent
- Exclusion Criteria:
- • Treatment with tamoxifen or other hormonal therapies as early breast cancer (EBC) adjuvant in the previous 24 weeks
- • Received radiotherapy within the past 4 weeks
- • History of systemic malignancy other than breast cancer within the previous 3 years
- • Estimated survival less than 24 weeks
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
St Petersburg, , Russian Federation
Odessa, , Ukraine
Praha 8, , Czech Republic
Donetsk, , Ukraine
Kharkiv, , Ukraine
Dnipropetrovsk, , Ukraine
Uzhgorod, , Ukraine
Yaroslavl, , Russian Federation
Arkhangelsk, , Russian Federation
St Petersburg, , Russian Federation
Belgorod, , Russian Federation
Kaliningarad, , Russian Federation
Kazan, Tatarstan, , Russian Federation
Ryazan, , Russian Federation
Patients applied
Trial Officials
Breast Cancer Established Brands Team Medical Science Director, MD
Study Director
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials